NovellusDx Tissue Collection Protocol

Completed

• Conditions: Patients Eligible for Tumor Biopsy; Patients That Have Been Diagnosed With Colorectal Cancer

• Registration Number: NCT01791322
• Lead Sponsor: Fore Biotherapeutics

Brief Summary

NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-02-12
• Study First Submitted QC: 2013-02-12
• Study First Posted: 2013-02-13
• Study Start: 2014-01
• Status Verified: 2015-10
• Primary Completion: 2016-06
• Study Completion: 2016-06
• Last Update Submitted: 2018-03-27
• Last Update Posted: 2018-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patients that have been diagnosed positive for colon cancer.
• available treatment follow up during cancer treatment

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correct identification of tumor mutant genes	up to 12 month	Correct identification of tumor mutant genes, in over 85% of the cases

Trial Locations

Locations (1)

Pathology Lab Hadassah Medical Center; 🇮🇱 Jerusalem, Israel